Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Nova Biomedical
| Company | Nova Biomedical |
|---|---|
| Name of analyzer | GloCyte Automated Cell Counter for CSF |
| City, State | Waltham, MA |
| Phone | 800-225-4034 |
| Website | |
| Analyzer application | diagnostic and research use |
| Dimensions of analyzer (H × W × D)/Analyzer footprint | 10.0 × 6.0 × 8.0 in./— |
| Country where analyzer was designed/Manufactured | U.S./U.S. |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S. (based on August 2026 survey deadline) | 2016/200 |
| First year analyzer sold outside U.S./Approximate No. of units installed outside U.S. (based on August 2026 survey deadline) | — |
| Foreign locations where company markets analyzer | U.K. (installed in U.K.) |
| Human languages (other than English) supported by analyzer | — |
| Analyzer list price | — |
| • Analyzer acquisition options | purchase |
| Training included with purchase/Total time for basic training per operator | yes/2 hours (at customer site or vendor office [user’s choice]) |
| • Follow-up training available | yes |
| Parameters that analyzer tests and reports | — |
| Types of testing FDA cleared or approved for analyzer | — |
| Types of body fluids FDA cleared or approved for analysis on analyzer | CSF |
| Analytical measurement range for body fluid | RBC count: 2–123 cells/µL (reportable range, 2–615,644 cells/µL); TNC count: 3–123 cells/µL (reportable range, 3–6,500 cells/µL) |
| Precision for body fluid | RBC count: 2.7–16.3%; TNC count: 2.5–18% |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | — |
| Differential methods used | — |
| Analytical measurement range: • WBC count/RBC count | WBC: — (TNC: 3–6,500 cells/µL)/RBC: 2–123 cells/µL (reportable range, 2–615,644 cells/µL) |
| Precision: • WBC count/RBC count | — |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | — |
| • Hemoglobin/Platelets | — |
| • Hematocrit/Reticulocytes | — |
| • Automated differential | — |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | — |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | — |
| Min. specimen volume open mode/Closed mode/Microsample capability | 60 µL/—/no |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | sample type, sample appearance, sample color, accession number, result/>100,000 results |
| Analyzer performs delta checks | no |
| Parameters for which flags may appear | control results out of range, expired reagents warning |
| • Flagging client selectable | yes |
| Analyzer recognizes and holds test results | yes, for potential test rerun (parameters for flags to hold samples defined by vendor) |
| Scattergram display uses cell-specific color | no |
| Histogram display uses color with thresholds | no |
| LIS interface formats supported | RS232, bidirectional |
| • Middleware interface | no (connects directly to LIS) |
| Analyzer transmits LOINC codes for results to LIS or middleware | yes |
| Lab automation system or workcells to which analyzer has a direct interface | none |
| Barcode symbologies read on specimen tube | Codabar, Data Matrix, Code 39, Code 128 |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | yes (supports QR codes) |
| No. of onboard reagents required for standard specimen analysis | 2 |
| • Reagents ready to use/Reagent tracking method | yes/RFID, barcode reader |
| Time required for analyzer maintenance | — |
| Onboard diagnostics for troubleshooting | yes |
| • Manufacturer can perform diagnostics via remote access | no |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/— |
| Distinguishing analyzer features (supplied by company) | 1 cell/µL limit of detection for RBCs and TNCs; consistent turnaround time for standarization and Lean practices; disposable test cartridges eliminate carryover |